Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mitochondrial Disease Clear all
Recruiting Phase 2 Interventional

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
KL1333, Placebo
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Orange, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 13, 2026, 5:01 AM EDT
Completed No phase listed Observational

Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)

NCT04350073
View directory record Official record
Conditions
COVID-19
Interventions
Q-NRG Metobolic Cart Device, MuscleSound Ultrasound, Multifrequency Bioimpedance Spectroscopy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 13, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Molecular Regulation of Muscle Glucose Metabolism

NCT01581736
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
U100 Humulin, Exercise
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Oct 13, 2026, 5:01 AM EDT
Recruiting No phase listed Observational

Natural History of MADD

NCT07734090
View directory record Official record
Conditions
Multiple Acyl-CoA Dehydrogenase Deficiency
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study of Zagociguat in Patients With MELAS

NCT06402123
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg, zagociguat 30mg, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants

NCT01624311
View directory record Official record
Conditions
Urea Cycle Disorders, Organic Acidemias
Interventions
Therapeutic Hypothermia, Standard of Care Therapy
Other
Lead sponsor
Uta Lichter-Konecki
Other
Eligibility
1 Day to 30 Days
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

NCT03506633
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Artery Disease
Interventions
MitoQ
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Not applicable Interventional

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

NCT00002034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 5:01 AM EDT
Completed No phase listed Observational

Neonatal CMV-Ganciclovir Follow-up Study

NCT00031421
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 14 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

NCT02693119
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy
Interventions
elamipretide (MTP-131) 1% topical ophthalmic solution, Vehicle topical ophthalmic solution
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Early Phase 1 Interventional Results available

Nicotinamide Riboside in LVAD Recipients

NCT03727646
View directory record Official record
Conditions
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
Interventions
Nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 13, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

NCT03564678
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Hyperbilirubinemia
Interventions
Levocarnitine, Vitamin B Complex
Dietary Supplement · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 13, 2026, 5:01 AM EDT
Recruiting Phase 2 Interventional

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
LX2006, Usual Care
Genetic · Other
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

NCT02805790
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Testosterone and Long Pulse Stimulation After SCI

NCT03345576
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Testosterone and LPWS, Testosterone and standard NMES
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy

NCT02161380
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy
Interventions
injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med), injection of scAAV2-P1ND4v2 2.4 X10e10vg (High), injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
Drug
Lead sponsor
Byron Lam
Other
Eligibility
15 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans

NCT02892331
View directory record Official record
Conditions
Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions
Moderate intensity exercise training (MOD-INT), High Intensity exercise training (HI-INT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

NCT01386970
View directory record Official record
Conditions
HIV
Interventions
zidovudine 300mg and lamivudine 150mg as Combivir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 13, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

(-)- Epicatechin Becker Muscular Dystrophy

NCT03236662
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
(-)-Epicatechin
Drug
Lead sponsor
Craig McDonald, MD
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 13, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men

NCT07161973
View directory record Official record
Conditions
Mitochondrial Energetics, Dietary Nitrate, Disuse Atrophy (Muscle) of Lower Leg
Interventions
Beetroot Juice - Active, Placebo Beetroot Juice Without Nitrate
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 44 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 13, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

NCT01970332
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Revascularization Surgery, Supervised exercise therapy
Procedure · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 13, 2026, 5:01 AM EDT
Withdrawn Phase 2 Interventional

Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01471652
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceutical supplements, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 13, 2026, 5:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 13, 2026, 5:01 AM EDT